Core Viewpoint - The company has received a medical device registration certificate from the National Medical Products Administration of China for its recombinant type I α1 collagen and sodium hyaluronate composite solution, marking a significant milestone in its product development and market expansion [1] Product Development - The product is the world's first recombinant collagen and sodium hyaluronate composite solution approved for improving cheek smoothness, showcasing the company's innovative capabilities [1] - This approval follows the successful registration of the recombinant type I α1 collagen freeze-dried fiber, further expanding the company's product matrix [1] Market Strategy - The company aims to steadily promote the product's market launch and distribution, leveraging a diverse product portfolio, comprehensive channel network, and refined brand management [1] - The introduction of this product is expected to inject new growth momentum into the company's business development in the skin rejuvenation sector [1]
巨子生物全资子公司收到国家药监局颁发的关于重组I型α1亚型胶原蛋白及透明质酸钠复合溶液产品的《中华人民共和国医疗器械注册证》